Recombinant Anti-Complement factor B antibody [EPR9288(B)] (ab133765)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR9288(B)] to Complement factor B
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Complement factor B antibody [EPR9288(B)]
See all Complement factor B primary antibodies -
Description
Rabbit monoclonal [EPR9288(B)] to Complement factor B -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: IHC-P or IP -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Human serum and plasma
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Dissociation constant (KD)
KD = 1.43 x 10 -10 M Learn more about KD -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR9288(B) -
Isotype
IgG
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab133765 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Detects a band of approximately 95, 60 kDa (predicted molecular weight: 86 kDa).
|
Notes |
---|
WB
1/1000 - 1/10000. Detects a band of approximately 95, 60 kDa (predicted molecular weight: 86 kDa). |
Target
-
Relevance
Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes. -
Cellular localization
Plasma membrane and Secreted -
Database links
- Entrez Gene: 629 Human
- Omim: 138470 Human
- SwissProt: P00751 Human
-
Alternative names
- C3/C5 convertase antibody
- Complement factor B antibody
- Glycine-rich beta glycoprotein antibody
see all
Images
-
All lanes : Anti-Complement factor B antibody [EPR9288(B)] (ab133765) at 1/1000 dilution
Lane 1 : Human serum
Lane 2 : Human plasma
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat anti-rabbit HRP conjugated antibody at 1/2000 dilution
Predicted band size: 86 kDa
Observed band size: 95 kDa why is the actual band size different from the predicted?
Additional bands at: 60 kDa (possible isoform)
Datasheets and documents
-
SDS download
-
Datasheet download
References (2)
ab133765 has been referenced in 2 publications.
- He C et al. Low CFB expression is independently associated with poor overall and disease-free survival in patients with lung adenocarcinoma. Oncol Lett 21:478 (2021). PubMed: 33968194
- Hayashi N et al. Multiple biomarkers of sepsis identified by novel time-lapse proteomics of patient serum. PLoS One 14:e0222403 (2019). PubMed: 31568522